Product nameAnti-EGFR (phospho Y1045) antibody [11C2]
See all EGFR primary antibodies
DescriptionMouse monoclonal [11C2] to EGFR (phospho Y1045)
Tested applicationsSuitable for: ELISA, WBmore details
Species reactivityReacts with: Mouse, Rat, Dog, Human
Synthetic peptide corresponding to Human EGFR (phospho Y1045) conjugated to keyhole limpet haemocyanin.
The phosphorylation status of Tyrosine 1045 regulates the degradation of activated EGFR. Autophosphorylation of Tyrosine 1045 creates a docking site for the c-cbl ubiquitination ligase.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage bufferPreservative: 0.09% Sodium azide
Constituents: 2.68% PBS, 50% Glycerol
Concentration information loading...
Purification notesThiophilic adsorption and size exclusion chromatography.
Primary antibody notesThe phosphorylation status of Tyrosine 1045 regulates the degradation of activated EGFR. Autophosphorylation of Tyrosine 1045 creates a docking site for the c-cbl ubiquitination ligase.
Our Abpromise guarantee covers the use of ab24928 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ELISA||Use a concentration of 0.05 µg/ml.|
|WB||Use a concentration of 0.01 µg/ml. Predicted molecular weight: 134 kDa.
Recommended blocking buffer CPPT: 0.5% (w/v) casein, 1% (w/v) PEG 4000, 1% (w/v) Polyvinylpyrrolidone (PVP), 0.1% Tween 20, 10mM Tris/HCl, pH 7.4, 150mM Sodium Chloride. Dilution optimised using Chromogenic detection.
FunctionReceptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, amphiregulin, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. May also activate the NF-kappa-B signaling cascade. Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling. Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin.
Isoform 2 may act as an antagonist of EGF action.
Tissue specificityUbiquitously expressed. Isoform 2 is also expressed in ovarian cancers.
Involvement in diseaseLung cancer
Inflammatory skin and bowel disease, neonatal, 2
Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family. EGF receptor subfamily.
Contains 1 protein kinase domain.
modificationsPhosphorylation at Ser-695 is partial and occurs only if Thr-693 is phosphorylated. Phosphorylation at Thr-678 and Thr-693 by PRKD1 inhibits EGF-induced MAPK8/JNK1 activation. Dephosphorylation by PTPRJ prevents endocytosis and stabilizes the receptor at the plasma membrane. Autophosphorylation at Tyr-1197 is stimulated by methylation at Arg-1199 and enhances interaction with PTPN6. Autophosphorylation at Tyr-1092 and/or Tyr-1110 recruits STAT3. Dephosphorylated by PTPN1 and PTPN2.
Monoubiquitinated and polyubiquitinated upon EGF stimulation; which does not affect tyrosine kinase activity or signaling capacity but may play a role in lysosomal targeting. Polyubiquitin linkage is mainly through 'Lys-63', but linkage through 'Lys-48', 'Lys-11' and 'Lys-29' also occurs. Deubiquitination by OTUD7B prevents degradation. Ubiquitinated by RNF115 and RNF126.
Methylated. Methylation at Arg-1199 by PRMT5 stimulates phosphorylation at Tyr-1197.
Cellular localizationSecreted and Cell membrane. Endoplasmic reticulum membrane. Golgi apparatus membrane. Nucleus membrane. Endosome. Endosome membrane. Nucleus. In response to EGF, translocated from the cell membrane to the nucleus via Golgi and ER. Endocytosed upon activation by ligand. Colocalized with GPER1 in the nucleus of estrogen agonist-induced cancer-associated fibroblasts (CAF).
- Information by UniProt
- Avian erythroblastic leukemia viral (v erb b) oncogene homolog antibody
- Cell growth inhibiting protein 40 antibody
- Cell proliferation inducing protein 61 antibody
All lanes : Anti-EGFR (phospho Y1045) antibody [11C2] (ab24928) at 0.5 µg/ml (EGFR Activation:
Serum starved MDA-MB 468 cells were incubated with 10ng/ml EGF for the indicated times. Whole cell lysates were prepared and separated by SDS-PAGE)
Lane 1 : control
Lane 2 : 5 min EGF
Lane 3 : 15 min EGF
Lane 4 : 30 min EGF
Lane 5 : 1 hour EGF
Lane 6 : 2 hours EGF
Lane 7 : 4 hours EGF
Lane 8 : 8 hours EGF
Lysates/proteins at 20000 cells per lane.
All lanes : A HRP-conjugated antibody
Developed using the ECL technique.
Predicted band size: 134 kDa
Exposure time: 30 seconds
Recommended blocking buffer CPPT: 0.5% (w/v) casein, 1% (w/v) PEG 4000, 1% (w/v) Polyvinylpyrrolidone (PVP), 0.1% Tween 20, 10mM Tris/HCl, pH 7.4, 150mM Sodium chloride.
This product has been referenced in:
- Jiang R et al. The long noncoding RNA lnc-EGFR stimulates T-regulatory cells differentiation thus promoting hepatocellular carcinoma immune evasion. Nat Commun 8:15129 (2017). WB, IP . Read more (PubMed: 28541302) »
- Currier MG et al. EGFR Interacts with the Fusion Protein of Respiratory Syncytial Virus Strain 2-20 and Mediates Infection and Mucin Expression. PLoS Pathog 12:e1005622 (2016). Read more (PubMed: 27152417) »